Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:58:24.214Z.
Calculation as of: 2026-10-06T18:58:24.214Z.
Quote observation: 2026-10-06T18:55:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 371c12db8760855cbd67a4f629ef705ee3b50919edbb0a0fc68f9f6d9159db17
PE RATIO
N/A
Market Cap
$169.85M
PE Ratio
N/A
TTM Avg
22.05
3Y Avg
43.38
5Y Avg
28.58
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quanterix Corporation (QTRX) | $164.40M | N/A | N/A | N/A | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.70M | 37.80 | 23.37 | 23.37 | 443.72 |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | N/A | 5.36 | 5.36 | 8.25 |
| Nkarta, Inc. (NKTX)vs › | $168.49M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.27M | N/A | 4.03 | 4.03 | 14.59 |
| PepGen Inc. (PEPG)vs › | $160.02M | N/A | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $168.99M | N/A | 7.76 | 7.76 | 7.76 |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A | N/A | N/A | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | N/A | 22.05 | 43.38 | 28.58 |
| Cue Biopharma, Inc. (CUE)vs › | $170.21M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.49
Forward EPS (Est.)
$-2.25
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
